NCT04510207View on ClinicalTrials.gov

A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above

PHASE3CompletedINTERVENTIONAL
Enrollment

44,101

Participants

Timeline

Start Date

July 16, 2020

Primary Completion Date

June 16, 2021

Study Completion Date

December 31, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Inactivated SARS-CoV-2 Vaccine (Vero cell)

The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP

BIOLOGICAL

Inactivated SARS-CoV-2 Vaccine (Vero cell)

The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by BIBP

BIOLOGICAL

Placebo

The placebo of inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP

Trial Locations (6)

11835

Katameya Medical Center, Cairo

22311

Vacsera health Care facilities , MoH, Cairo

51900

Sheikh Khalifa Medical City, SEHA, Abu Dhabi

61545

Al Qarain Primary Health Care Centre-MOHAP, Sharjah city

Unknown

Bahrain International Exhibition & Convention Centre Affiliated to Salymynia Medical Complex S, Sanābis

Prince Hamza Hospital, Amman

Sponsors

Collaborators (1)

G42 Healthcare company
All Listed Sponsors
collaborator

G42 Healthcare company

UNKNOWN

collaborator

Abu Dhabi Health Services Company

OTHER_GOV

collaborator

Wuhan Institute of Biological Products Co., Ltd

INDUSTRY

collaborator

Beijing Institute of Biological Products Co Ltd.

INDUSTRY

lead

China National Biotec Group Company Limited

INDUSTRY

NCT04510207 - A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above | Biotech Hunter | Biotech Hunter